Background Transporting over two billion passengers per year, global airline travel has the potential to spread emerging infectious diseases, both via transportation of infectious cases and through in-flight transmission. Current World Health Organization (WHO) guidance recommends contact tracing of passengers seated within two rows of a case of influenza during air travel.
Introduction
An emergent novel swine-origin influenza A(H1N1)pdm09 virus was first identified in humans on 15th April 2009; on 25th April 2009, the World Health Organization declared the outbreak a 'public health emergency of international concern'. 1 The subsequent influenza pandemic spread from Mexico to at least 214 countries with over 18 000 laboratoryconfirmed deaths worldwide, with the true burden of disease many times greater. 2, 3 With over 2 billion passengers per year, global airline travel represents an important vehicle for the spread of emerging infectious diseases such as pandemic influenza, both through the transportation of infected passengers and through the potential for in-flight transmission of disease. Previous studies have described the spread of influenza during air travel, 4, 5 including five reports of transmission of influenza A(H1N1)pdm09 on commercial flights. [6] [7] [8] [9] [10] Current World Health Organization (WHO) technical advice for case management of influenza infection in-flight includes specific measures to reduce transmission and recommends the completion of passenger locator cards to facilitate subsequent contact tracing of passengers seated within two rows of an infected case. 11 The aims of this study are to describe the in-flight transmission of influenza A(H1N1)pdm09 during a commercial flight carrying the first cases reported in the United Kingdom and to test the specific hypothesis that passengers seated within two rows of an infected case are at greater risk of infection. Knowledge of in-flight transmission dynamics of influenza A(H1N1)pdm09 will inform public health policy regarding advice on dealing with potentially infectious passengers and the role, if any, of contact tracing.
Methods
On 27th April 2009, a couple returning by air travel from vacation in Mexico became the first case of influenza A (H1N1)pdm09 to be reported to the public health agencies in the United Kingdom (UK). The couple travelled on a Boeing 767-300 that departed Cancun, Mexico, at 0000 GMT on 21st April 2009, and arrived in Birmingham, UK, 9Á5 hours later. This cohort study, supplemented by multiple overlapping data sources, examines possible transmission dynamics between passengers travelling on board the same commercial flight.
Data sources
The data sources used were an historical cohort study using a telephone questionnaire administered following the flight; initial contact tracing of passengers seated within two rows of the first identified case and enhanced surveillance data collected by the Health Protection Agency (HPA) at the time of the pandemic.
Historical cohort study A flight manifest was obtained to identify a study cohort, the sampling frame of which comprised all passengers travelling on the flight. The HPA attempted to contact all passengers to request completion of a telephone-administered questionnaire to investigate demographics, location of stay and activities in Mexico, travelling group links and symptoms. Passengers were asked which seat they sat in, as some did not take up their allocated seat. Eight public health officials conducted the interviews between 9th June 2009 and 5th August 2009. Passengers unable to be contacted by telephone after three attempts were sent an invitation to participate by post, but there were no further responses to this. All passengers contacted were invited to attend for serological testing (see section Laboratory testing).
Contact tracing
The West Midlands HPA regional epidemiology unit attempted to contact those seated within two rows of the first two reported cases on the flight, to assess case status and the individual passenger's need for antiviral medication. All contact tracing was performed between 29th April 2009 and 1st May 2009, by two officials.
HPA enhanced surveillance data Data linkage was used to cross-match the flight manifest with HPA information collected at the time of the pandemic using the first few hundred (FF100) and Data Mart surveillance systems. 12 The FF100 surveillance system collected detailed demographic and clinical data via interviews and review of clinical records from the first 392 reported laboratory cases of influenza A(H1N1)pdm09 in the UK. The Data Mart project was developed during the pandemic as an automated surveillance tool to collect H1N1 testing information from UK laboratories, in an effort to improve timeliness and completion of reporting. Data Mart data fields include clinical information and the results of PCR testing.
Definition of Influenza-like illness and case status of cohort subjects
The USA Centre for Disease Control and Prevention (CDC) clinical definition of influenza-like illness (ILI) was used, defined as fever (self-reported in this study), with at least one symptom of sore throat or cough.
To establish the case status of passengers, an incubation time for influenza A(H1N1)pdm09 of 0-6 days was used, with a period of communicability from 1 day pre-to 1 day post-symptom resolution. 13 The case status of subjects in the cohort was defined as infectious in-flight; immune in-flight; infection acquired in-flight; non-case; and unknown. 9 Infectious in-flight (Infectious) Any passenger with symptoms compatible with ILI and onset prior to the day of the flight, with recovery of symptoms no earlier than the day before the flight.
Immune in-flight (Immune) Any passenger with a history of symptoms compatible with ILI, but who had recovered at least 2 days before the flight.
Infection acquired in-flight (Infected in-flight) Any passenger with a history of symptoms compatible with ILI that began 0-6 days after the day of the flight.
Non-case (non-case)
A passenger with clinical data who did not have symptoms consistent with ILI or a date of onset more than 6 days post-flight.
Statistical analysis
All data analysis was performed using Stata 12.0 (Stata Corp., College Station, TX, USA). As the data sources were overlapping, they were considered to be a hierarchy, with the cohort study considered the most complete and reliable for clinical data, followed by contact tracing and then laboratory surveillance data. Initial descriptive analysis was performed, mapping the flight seating plan, followed by calculation of the attack rate and testing the primary hypothesis using Fisher's exact test.
Laboratory testing
Combined nose and throat swab specimens were analysed by RT-PCR for detection of influenza A (H1N1)pdm09 virus as 14 Blood samples for serological testing were collected by study nurses and shipped to the HPA laboratory (Colindale, London, UK), where serum was separated and stored at À20°C until analysed. Antibody responses were detected by haemagglutination inhibition (HI) according to the standard methods. 15 Sera and specific positive and negative control sera were treated with receptordestroying enzyme (RDE II) (Denka Seiken Co., Ltd., Tokyo, Japan) according to manufacturer's protocol to remove nonspecific inhibitors. HI antibody titres were determined in duplicate for each serum using four haemagglutinating units (HA units) of either NIBRG121 or NIBRG122 (reverse genetics viruses with PR8 backbone and NA and HA components of the A/California/7/2009 and A/England/ 195/2009 viruses, respectively) and a suspension of Turkey red blood cells. Titres were expressed as the reciprocal of the highest dilution of serum completely inhibiting the haemagglutination reaction. Single samples with titres ≥1:32 by HI were considered seropositive, suggestive of recent infection with influenza A(H1N1)pdm09. Table 1 demonstrates the results of serological and PCR testing by case status for passengers on the flight. In total, 30 passengers had PCR testing with seven positive for influenza A(H1N1)pdm09. Serology testing was available for 96 of 239 (40Á2%) passengers (two infected in-flight and 94 non-cases).
Results
Clinical data sufficient to establish a case definition were available for 239 of the 278 (86Á0%) passengers who travelled on the flight of which 224 were part of the cohort study; an additional 12 were added through contact tracing. Enhanced surveillance data were available for 17 passengers, but only contributed information regarding an additional three cases. Ten passengers were defined clinically as infected in-flight, leading to an overall attack rate of 10 of 232 at risk (4Á3%; 95% CI 1Á7-6Á9%). Of the ten passengers defined as infected in-flight, four were tested using PCR, and of these, 4 of 4 (100%) were positive, one PCR positive case was also serology positive, and a further passenger who did not undergo PCR testing was serology negative. Six passengers were defined as infectious, of whom four underwent PCR testing, with one-fourth (25%) testing positive; no infectious cases underwent serological testing. One passenger was defined as immune during the flight and underwent no laboratory testing. Figure 1 demonstrates the seating plan for the flight; eight infected in-flight cases were seated in the rear section of the plane, with one seated at the front. The seat location of one infected in-flight case was unknown. Infectious cases were seated in all sections of the flight. There was no evidence that passengers seated within two rows of an infectious case were at an increased risk of infection compared with those who were not (relative risk 0Á9; 95% CI 0Á2-3Á1), with the attack rates similar for both groups (5 of 131, 3Á8%; 95% CI 0Á5%-7Á1% versus 4 of 89, 4Á5%; 95% CI 0Á1-8Á9%; P = 1Á00); seating data were unavailable for 12 passengers at risk. 
Other potential modes of contact
Apart from the first two UK-reported cases, infectious case 5 and infected in-flight case 13 (Table 2) , no other passengers infected in-flight had travelled in Mexico with infectious cases. Further information gathered for the 224 participants in the cohort study did not reveal any specific links with resorts in Mexico, with only three of eight (two unknown) of the infected in-flight passengers staying at resorts where those considered infectious had been on vacation; infected in-flight n/a n/a
n/a n/a 0/1 (0Á0) n/a n/a 
1 cases 9 and 10 stayed at the same resort as infectious case 2; infected in-flight case 16 stayed at the same resort as infectious case 4. All passengers travelled to the airport on tour buses, an estimated journey time of 30-120 minutes depending on starting location. Where information was available, passengers with ILI stayed at either Cancun (two infectious, five infected in-flight), Riviera Maya (three infectious, one immune, two infected in-flight) or Akumal (one infected inflight). Cancun is north of Cancun airport, whereas Riviera Maya and Akumal are south; therefore, it seems unlikely that these passengers travelled together to the airport. No apparent links between those with ILI could be attributed to day trips and visits while in Mexico.
There was no association between time spent in the departure lounge and being infected in-flight (OR trend 1Á1, 95% CI 0Á4-3Á0; P = 0Á88). Four of eight (50%; two missing data) of the infected in-flight cases spent more than two hours in the departure lounge compared with 114 of 208 (54Á8%; 14 missing data) of non-cases.
Participants in the cohort study were asked about toilet use on board the flight, one infectious case used the front right toilet, with information not available for the remaining five. The relative risk of infection by exposure to the toilet used by infectious cases could therefore not be calculated. Six of ten cases infected in-flight provided information on toilet use, using three different toilets, with two using the front right toilet. Data regarding movement in-flight were available for five of the six infectious passengers, with one stating they spent 1-2 hours away from their seat and a further two away from their seat for over two hours, whereas all infected inflight cases spent <1 hour away from their allocated seat.
Discussion

Main findings
This study estimates the overall attack rate (AR) for influenza A(H1N1)pdm09 on a nine-hour commercial flight with six potentially infectious passengers on board to be 4Á3%, but did not demonstrate an increased risk to those seated within two rows of an infectious case.
The AR in our present study is largely consistent with the published data from four previous reports that have suggested transmission of influenza A(H1N1)pdm09 during long-haul modern commercial air travel; 0Á5% for all sections of a 13-hour flight with a single infectious passenger 8 ; 4Á7% in a single section of a 15-hour flight with a single infectious passenger 10 ; 1Á9% in a single section containing 12 infective passengers on a 13-hour flight 9 ; 2Á4% estimated using pooled data from four flights of between 1Á5-and 2Á5-hour durations. 16 Han et al. 7 reported a single case (AR 1Á1%) infected on a 45-minute flight containing two infectious cases.
Our study does not demonstrate an increased risk of becoming infected with influenza A(H1N1)pdm09 in those seated within two rows of an infectious case compared with those who were not. Two separate reports of single cases infected in-flight demonstrated that they sat two and six rows away from the known infectious case. 7, 8 Ooi et al. 10 demonstrated that contact tracing of passengers within two rows of an infectious case would have only detected two of five of cases newly infected on a long-haul flight with a single known infectious passenger. The attack rate for those seated within two rows of any of 12 infectious cases on a flight from Los Angeles to Auckland was shown to be two of 57 (3Á5%) compared with 0 of 46 for those seated elsewhere, with only the rear section of the plane studied. 9 Following the study of two long-haul flights, Foxwell et al. 6 suggested that the risk of contracting influenza A(H1N1)pdm09 from fellow passengers was increased by 1Á4% (95% CI 0Á5-3Á4%) in those seated within two rows of an infectious case, but the overall response rate in this study was low at 43%, raising the possibility of selection bias. An investigation of two flights landing in North America, of between 1Á5-and 2Á5-hour duration, demonstrated a risk ratio of 3Á0 (95% CI 0Á7-12Á7) for those seated within two rows of an infectious case of influenza A(H1N1)pdm09 compared with those who were not. 16 The results of laboratory testing in this present study are largely consistent with the clinical case definitions. All four infected in-flight cases tested using PCR were positive, suggesting specificity of the CDC clinical case definition; only one of four infectious cases tested was positive, but this is unsurprising given the length of time (5-15 days) between symptom onset in Mexico and return to the UK. Of the four infected in-flight cases confirmed using PCR testing, two of Figure 2 . Epidemic Curve by case status (n = 17). four (50%) cases were seated within two rows of an infectious case (RR 0Á7; 95% CI 0Á10-4Á7). Serological testing was only available for two cases (both infected in-flight) with ILI and was negative in one case with a previously positive PCR, perhaps as a result of early timing of the test or a falsenegative result following administration of oseltamivir. Serological data were considered in the light of potential cross-reactivity of antibody from seasonal influenza A (H1N1) 15 ; antibody titres ≥1:32 by HI were only considered 'suggestive', not as confirmation of previous infection. Furthermore, serological data were only interpreted in the context with additional information, namely PCR and ILI data.
Influenza transmission in-flight can occur via several pathways: direct physical contact, fomites, direct droplet spread and suspended small particles. 17 Aircraft cabins contain air that is recycled through high-efficiency particulate air (HEPA) filtration via a laminar flow pattern, reducing longitudinal spread fore and aft of the vessel. 18 The risk of airborne transmission of pathogens is therefore likely to be greatest in adjacent rows, although computational studies have demonstrated spread of droplets up to seven rows within 4 minutes 19 ; also perturbations of airflow are likely to occur as passengers walk through the cabin. 20 Influenza virus-containing aerosol shedding can occur during normal tidal breathing, leading to suspension of particles in ambient air and potential disease transmission during air travel. 21, 22 In one study, 70% of exhaled aerosol particles in subjects with influenza were between 0Á3 lm and 0Á5 lm, 23 therefore largely removed if passed through HEPA filtration. 24 Low absolute humidity on aircraft has the theoretical potential to increase influenza survival and transmission. 17 Using quantitative microbial risk assessment, Wagner et al. 25 demonstrated that the risk of contracting influenza A(H1N1)pdm09 is unlikely to extend beyond each individual cabin and is lower in first compared with economy class; their estimates of 5-10 new infections from a single case over an 11-hour flight are consistent with the findings of this present study.
Limitations
Limitations of this study include selection and measurement biases, limited sample size and the potential for influenza A (H1N1)pdm09 transmission beyond the flight.
Information sufficient to determine case status was available for 239 of 278 (86Á0%) passengers on board the flight, with more detailed clinical data obtained from 224 of 278 (80Á6%) passengers, the high response reducing the potential effect of selection bias. No data are available regarding the demographics or case status of non-responders to the cohort study and contact tracing exercise, unless recorded during enhanced surveillance. However, there is no suggestion that this group were aware of, and therefore could be selected by, the exposure studied. The majority of passengers with unknown case status belonged to groups of four to six travellers, where only contact details of the lead passenger were available, further suggesting that nonresponse was unrelated to individual case status or exposure, and therefore unlikely to bias the results of this study. The use of a clinical case definition has the potential to result in incorrect classification of case status, thereby under-or overestimating the attack rate. The specificity of 100% for the four infected in-flight cases tested with PCR provides some validation to the CDC case definition chosen. The validity of defining true infectious cases was potentially reduced by the low PCR positivity rate (1 of 4; 25%) and lack of serological testing among this group. The potential for observer bias was minimised as interviewers would not be aware of the location of infectious cases in the cohort study, but recall bias among respondents aware of the reported cases remains a possibility.
Despite the large number of passengers on the flight, the low attack rate reduces the power in this study to test the primary hypothesis, the AR in those seated or not seated within two rows of an infectious case was almost identical, but a much larger study, in practical terms a meta-analysis of several flights, would be required to test the hypothesis with statistical integrity.
In calculating the AR, the presumption is made that all newly infected cases contracted influenza A(H1N1)pdm09 during the course of the flight, but this requires the validity of several assumptions. The incubation period used in this study was 0-6 days, estimated from modelling studies among the UK population following the pandemic. 13 A systematic review of influenza A suggested an incubation period of 0Á7-2Á8 days, but a longer time period in this study was used because it is influenza A(H1N1)pdm09 specific and onset of disease up to 6 days after the flight was considered more likely to be from passenger contacts than elsewhere. 26 Reported median incubation periods for influenza A(H1N1)pdm09 include 0Á8, 2Á1, 3 and 4Á3 days, all consistent with the pattern of the epidemic curve in this present study. 13, [27] [28] [29] Despite the first reported cases of influenza A(H1N1) pdm09 arriving on the flight studied, there is evidence to suggest circulating disease in the UK prior to this. A phylogenetic study estimated from divergence that two of 13 strains of influenza A(H1N1)pdm09 may have been circulating up to 8 days before the arrival of the flight, although the risk of transmission to the passengers studied remains unknown. 30 Exhaustive attempts were made in the cohort study to identify common links, such as accommodation and excursions in Mexico, family groups and toilet use on board. No clear links were identified apart from that between infectious case 5 and infected in-flight case 13, but the potential for becoming infected prior to the flight in Mexico remains for all infected passengers, and therefore the AR may be an overestimate.
Other potential opportunities for infection include via aerosol spread while travelling in close proximity to an infectious case on a low-humidity air-conditioned charter bus to the airport and via direct contact in a potentially crowded departure lounge.
At the time of the cohort study, the aircraft toilet locations were not known to health protection staff, and there is likely to be considerable non-differential misclassification in self-reported use. Therefore, any increased risk of illness, if present, associated with using the same toilet as an infectious case was unlikely to be identified by this study. The onset of symptoms 5-15 days prior to the flight for infectious cases raises the possibility of resort exposure leading to the infection of those infected in-flight and demonstrates the additional possible exposure to circulating disease in Mexico at the time of the flight. The shape of the epidemic curve, albeit for a small number of cases, does suggest increased transmission around the time of the flight.
Implications for public health policy
The findings of this study do not support current WHO guidance regarding the contact tracing of passengers seated within two rows of an infectious case of influenza A(H1N1) pdm09. The complex transmission dynamics of influenza, including airborne, direct and surface transmission, make clear identification of those at risk and decisions about subsequent contact tracing challenging. 30 Further cohort studies after the identification of infectious passengers, followed by meta-analysis of data, are required to validate or refine current guidance.
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